DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

AK-Fluor (Fluorescein Sodium) - Published Studies


AK-Fluor Related Published Studies

Well-designed clinical trials related to AK-Fluor (Fluorescein)

Minimized cardiopulmonary bypass reduces retinal microembolization: a randomized clinical study using fluorescein angiography. [2011.01]

Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. [2010.11]

Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9. [2010.09]

Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. [2010.05]

NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. [2010.02]

[Effects of Huoxue Tongmai Lishui method on fundus fluorescein angiography of non-ischemic retinal vein occlusion: a randomized controlled trial] [2009.11]

Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein. [2008.10]

The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. [2007.12]

Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. [2007.05]

Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography. [2007.01]

Well-designed clinical trials possibly related to AK-Fluor (Fluorescein)

Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. [2014]

Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. [2014]

Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema. [2014]

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. [2014]

Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. [2014]

Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. [2013]

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. [2013]

Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. [2013]

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. [2012]

Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. [2012]

Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. [2012]

Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. [2012]

Clinical benefits of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens users. [2012]

Noninvasive, Objective, Multimodal Tear Dynamics Evaluation of 5 Over-the-Counter Tear Drops in a Randomized Controlled Trial. [2011.12.01]

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]

Intravitreal Bevacizumab for Treatment of Subfoveal Idiopathic Choroidal Neovascularization: Results of a 1-Year Prospective Trial. [2011.10.06]

Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. [2011.10]

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. [2011.08]

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. [2011.08]

Visual effect and residence time of artificial tears in dry eye subjects. [2011.07]

A preliminary study of silicone hydrogel lens material and care solution bioincompatibilities. [2011.07]

Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. [2011.07]

Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. [2011.06.17]

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. [2011.06]

The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. [2011.05]

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. [2011.05]

Age-related variations of human tear meniscus and diagnosis of dry eye with Fourier-domain anterior segment optical coherence tomography. [2011.05]

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. [2011.04]

Internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole: a pragmatic randomized controlled trial. [2011.03.01]

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. [2011.03]

Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. [2011.03]

Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. [2011.02]

Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. [2011.02]

Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial. [2011.02]

[The effect of recombinant bovine basic fibroblast growth factor on the LASIK-induced neurotrophic epitheliopathy and the recovery of corneal sensation after LASIK]. [2011.01]

Zinc salts provide a novel, prolonged and rapid inhibition of gastric acid secretion. [2011.01]

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. [2011.01]

Selective retina therapy for acute central serous chorioretinopathy. [2011.01]

A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. [2011]

Evaluation of the role of vascular endothelial growth factor in diabetic retinopathy. [2011]

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011]

Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. [2011]

[Efficacy assessment of Nutrilarm®, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome]. [Article in French] [2011]

Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. [2011]

Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. [2011]

Efficacy and safety of netilmycin/dexamethasone preservative-free and tobramycin/dexamethasone-preserved fixed combination in patients after cataract surgery. [2010.12]

Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. [2010.12]

Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. [2010.12]

Adherent ocular bandage for clear corneal incisions used in cataract surgery. [2010.11]

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. [2010.11]

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. [2010.11]

Upper punctal occlusion versus lower punctal occlusion in dry eye. [2010.11]

Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. [2010.10]

Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. [2010.10]

A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.10]

Inverted internal limiting membrane flap technique for large macular holes. [2010.10]

Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. [2010.09]

A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. [2010.08]

Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. [2010.08]

Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. [2010.07]

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. [2010.07]

Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. [2010.06]

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. [2010.06]

Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification. [2010.06]

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. [2010.06]

Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. [2010.06]

Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. [2010.06]

Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: The Manchester Pascal Study. [2010.05]

Classification and treatment of radiation maculopathy. [2010.05]

The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. [2010.05]

Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. [2010.05]

In vivo laser-tissue interactions and healing responses from 20- vs 100-millisecond pulse Pascal photocoagulation burns. [2010.04]

Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. [2010.04]

Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness. [2010.04]

Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. [2010.04]

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. [2010.04]

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. [2010.04]

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. [2010.04]

Visual outcomes in five different approaches for treatment of central retinal vein occlusion. [2010.03]

Does the length of intubation affect the success of treatment for congenital nasolacrimal duct obstruction? [2010.03]

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. [2010.03]

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. [2010.03]

Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. [2010.03]

Effect of oral prednisolone on visual outcomes and complications after scleral buckling. [2010.03]

Polypoidal choroidal vasculopathy: an angiographic discussion. [2010.03]

Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. [2010.02]

Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: a flow cytometric study. [2010.02]

The Graft Imaging to Improve Patency (GRIIP) clinical trial results. [2010.02]

Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. [2010.02]

Effect of nasolacrimal duct obstruction on nasal mucociliary transport. [2010.02]

Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. [2010.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017